IL283566A - Antibody that binds to vegf and il-1beta and methods of use - Google Patents
Antibody that binds to vegf and il-1beta and methods of useInfo
- Publication number
- IL283566A IL283566A IL283566A IL28356621A IL283566A IL 283566 A IL283566 A IL 283566A IL 283566 A IL283566 A IL 283566A IL 28356621 A IL28356621 A IL 28356621A IL 283566 A IL283566 A IL 283566A
- Authority
- IL
- Israel
- Prior art keywords
- 1beta
- antibody
- methods
- binds vegf
- vegf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215023 | 2018-12-21 | ||
| PCT/EP2019/086529 WO2020127873A1 (en) | 2018-12-21 | 2019-12-20 | Antibody that binds to vegf and il-1beta and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL283566A true IL283566A (en) | 2021-07-29 |
Family
ID=64870356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283566A IL283566A (en) | 2018-12-21 | 2021-05-30 | Antibody that binds to vegf and il-1beta and methods of use |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11130804B2 (uk) |
| EP (1) | EP3898671A1 (uk) |
| JP (4) | JP7114813B2 (uk) |
| KR (2) | KR20240042566A (uk) |
| CN (6) | CN119708249A (uk) |
| AR (1) | AR117468A1 (uk) |
| AU (1) | AU2019406712B2 (uk) |
| BR (1) | BR112021012022A2 (uk) |
| CL (1) | CL2021001616A1 (uk) |
| CO (1) | CO2021008755A2 (uk) |
| CR (1) | CR20210332A (uk) |
| IL (1) | IL283566A (uk) |
| MX (1) | MX2021007421A (uk) |
| MY (1) | MY199149A (uk) |
| PE (1) | PE20211294A1 (uk) |
| PH (1) | PH12021551470A1 (uk) |
| SG (1) | SG11202106198YA (uk) |
| TW (2) | TWI853867B (uk) |
| UA (1) | UA129264C2 (uk) |
| WO (1) | WO2020127873A1 (uk) |
| ZA (1) | ZA202103643B (uk) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020127873A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and il-1beta and methods of use |
| CN116323663A (zh) | 2020-09-04 | 2023-06-23 | 豪夫迈·罗氏有限公司 | 与vegf-a和ang2结合的抗体及其使用方法 |
| EP4585894A4 (en) | 2022-09-07 | 2025-12-31 | Sumitomo Electric Industries | OPTICAL CHARACTERISTICS MEASUREMENT DEVICE AND METHOD FOR MEASURING OPTICAL CHARACTERISTICS |
| CN122161849A (zh) | 2023-11-09 | 2026-06-05 | 豪夫迈·罗氏有限公司 | 具有条件性活性的多特异性抗体 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US830930A (en) | 1905-11-22 | 1906-09-11 | E & T Fairbanks & Co | Weighing-scale. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| ATE297452T1 (de) | 1998-07-23 | 2005-06-15 | Avebe Coop Verkoop Prod | Klebemittelzusammensetzung |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| KR101498588B1 (ko) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도 |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0607315B1 (pt) | 2005-02-07 | 2022-05-17 | Roche Glycart Ag | Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| KR20150036824A (ko) | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
| CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| SG195196A1 (en) | 2011-05-27 | 2013-12-30 | Dutalys | Dual targeting |
| KR102069397B1 (ko) | 2012-02-15 | 2020-01-22 | 에프. 호프만-라 로슈 아게 | Fc-수용체 기재 친화성 크로마토그래피 |
| SI3495387T1 (sl) | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| CA2891566A1 (en) * | 2012-12-05 | 2014-06-12 | Dutalys Gmbh | Dual targeting |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック, インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| JP2017537896A (ja) * | 2014-11-10 | 2017-12-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二重特異性抗体及び眼科に使用する方法 |
| SG11201702550WA (en) * | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| WO2017079768A1 (en) * | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
| JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ |
| WO2018210898A1 (en) * | 2017-05-18 | 2018-11-22 | F. Hoffmann-La Roche Ag | Reduction of application-related side reaction of a therapeutic antibody |
| WO2020127873A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and il-1beta and methods of use |
-
2019
- 2019-12-20 WO PCT/EP2019/086529 patent/WO2020127873A1/en not_active Ceased
- 2019-12-20 CN CN202411953347.8A patent/CN119708249A/zh active Pending
- 2019-12-20 AU AU2019406712A patent/AU2019406712B2/en active Active
- 2019-12-20 CN CN202411953344.4A patent/CN119708248A/zh active Pending
- 2019-12-20 UA UAA202104073A patent/UA129264C2/uk unknown
- 2019-12-20 CN CN202411953327.0A patent/CN119708246A/zh active Pending
- 2019-12-20 CN CN202411953333.6A patent/CN119708247A/zh active Pending
- 2019-12-20 PE PE2021000884A patent/PE20211294A1/es unknown
- 2019-12-20 MY MYPI2021003408A patent/MY199149A/en unknown
- 2019-12-20 BR BR112021012022A patent/BR112021012022A2/pt unknown
- 2019-12-20 TW TW108146845A patent/TWI853867B/zh active
- 2019-12-20 AR ARP190103792A patent/AR117468A1/es unknown
- 2019-12-20 KR KR1020247009946A patent/KR20240042566A/ko not_active Ceased
- 2019-12-20 TW TW113131340A patent/TWI921882B/zh active
- 2019-12-20 SG SG11202106198YA patent/SG11202106198YA/en unknown
- 2019-12-20 US US16/722,317 patent/US11130804B2/en active Active
- 2019-12-20 KR KR1020217020190A patent/KR102652720B1/ko active Active
- 2019-12-20 CN CN202411953337.4A patent/CN119751690A/zh active Pending
- 2019-12-20 JP JP2021535578A patent/JP7114813B2/ja active Active
- 2019-12-20 MX MX2021007421A patent/MX2021007421A/es unknown
- 2019-12-20 CN CN201980084480.5A patent/CN113195531B/zh active Active
- 2019-12-20 EP EP19836489.5A patent/EP3898671A1/en active Pending
- 2019-12-20 CR CR20210332A patent/CR20210332A/es unknown
- 2019-12-20 PH PH1/2021/551470A patent/PH12021551470A1/en unknown
-
2021
- 2021-05-27 ZA ZA2021/03643A patent/ZA202103643B/en unknown
- 2021-05-30 IL IL283566A patent/IL283566A/en unknown
- 2021-06-17 CL CL2021001616A patent/CL2021001616A1/es unknown
- 2021-07-01 CO CONC2021/0008755A patent/CO2021008755A2/es unknown
- 2021-09-08 US US17/469,044 patent/US11866490B2/en active Active
-
2022
- 2022-07-27 JP JP2022119854A patent/JP7342212B2/ja active Active
-
2023
- 2023-08-30 JP JP2023139510A patent/JP7680504B2/ja active Active
- 2023-11-15 US US18/510,174 patent/US20240101657A1/en active Pending
-
2025
- 2025-05-08 JP JP2025078193A patent/JP2025121995A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3325513B1 (en) | Anti-PD-L1 antibodies and their uses | |
| IL272069A (en) | Dosage regimens of anti-lag-3 antibodies and uses thereof | |
| PT3802608T (pt) | Anticorpos anti-cd3 e utilizações destes | |
| EP3740224A4 (en) | ANTI-LILRB ANTIBODIES AND THEIR USES | |
| IL284369A (en) | Antibody against human il-4ra and use thereof | |
| IL289354A (en) | Anti-cd154 antibodies and uses thereof | |
| IL262095A (en) | Anti-pacap antibodies and uses thereof | |
| EP3621642C0 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES | |
| LT3618928T (lt) | Anti-sortilino antikūnai ir jų panaudojimo būdai | |
| IL280317A (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| PL3601358T3 (pl) | Przeciwciała anty-trem2 i sposoby ich wykorzystania | |
| EP3904382A4 (en) | ANTI-IL-23P19 ANTIBODIES AND USES THEREOF | |
| IL263657A (en) | Anti-c5 antibodies and methods of use | |
| IL259747A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| EP3856245A4 (en) | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF | |
| EP3532100A4 (en) | ANTI-PD-L1 ANTIBODIES AND VARIANTS | |
| IL283104A (en) | Antagonistic cd40 monoclonal antibodies and uses thereof | |
| IL269074A (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| IL282424A (en) | Alk2 antibodies and methods of use thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| LT3525583T (lt) | Anti-c1s antikūnai ir jų naudojimo būdai | |
| EP4071172A4 (en) | ANTI-LILRB1 ANTIBODIES AND ITS USES | |
| EP4025609A4 (en) | ANTI-STEAP1 ANTIBODIES AND THEIR USES | |
| PT3280440T (pt) | Anticorpos anti-c1s humanizados e métodos de utilização destes | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof |